Anti-CD70 and BCR-ABL inhibitor combination therapy
摘要:
Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
信息查询
0/0